HC Wainwright Reaffirms Buy Rating for Evolus (NASDAQ:EOLS)

HC Wainwright reiterated their buy rating on shares of Evolus (NASDAQ:EOLS) in a research note published on Thursday,Benzinga reports. They currently have a $27.00 price objective on the stock.

Other analysts also recently issued reports about the stock. Barclays lifted their price objective on shares of Evolus from $16.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, September 13th. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Evolus in a research report on Friday, September 13th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Evolus in a research note on Monday, September 16th.

Evolus Stock Down 4.3 %

EOLS stock traded down $0.61 during mid-day trading on Thursday, hitting $13.68. 1,276,296 shares of the company were exchanged, compared to its average volume of 588,565. The firm has a market cap of $863.07 million, a P/E ratio of -15.70 and a beta of 1.31. Evolus has a 1-year low of $7.74 and a 1-year high of $17.82. The company has a debt-to-equity ratio of 6.26, a quick ratio of 2.67 and a current ratio of 2.92. The firm’s 50 day simple moving average is $16.26 and its 200 day simple moving average is $13.83.

Evolus (NASDAQ:EOLS) last released its earnings results on Wednesday, November 6th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.09). The business had revenue of $61.09 million during the quarter, compared to analysts’ expectations of $62.81 million. On average, sell-side analysts predict that Evolus will post -0.64 EPS for the current fiscal year.

Insider Transactions at Evolus

In other news, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $15.85, for a total value of $89,251.35. Following the completion of the sale, the chief marketing officer now directly owns 82,375 shares in the company, valued at $1,305,643.75. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. In other Evolus news, CFO Sandra Beaver sold 3,276 shares of the company’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the completion of the transaction, the chief financial officer now owns 148,502 shares in the company, valued at $2,224,559.96. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the firm’s stock in a transaction on Friday, August 30th. The shares were sold at an average price of $15.85, for a total value of $89,251.35. Following the sale, the chief marketing officer now directly owns 82,375 shares of the company’s stock, valued at approximately $1,305,643.75. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 6.10% of the company’s stock.

Institutional Trading of Evolus

Large investors have recently added to or reduced their stakes in the stock. Oppenheimer & Co. Inc. bought a new position in shares of Evolus during the 3rd quarter valued at approximately $212,000. GSA Capital Partners LLP boosted its position in Evolus by 335.3% during the 3rd quarter. GSA Capital Partners LLP now owns 120,964 shares of the company’s stock valued at $1,960,000 after acquiring an additional 93,176 shares in the last quarter. Rice Hall James & Associates LLC grew its holdings in shares of Evolus by 6.3% during the 3rd quarter. Rice Hall James & Associates LLC now owns 904,900 shares of the company’s stock worth $14,659,000 after acquiring an additional 53,605 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Evolus by 65.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,135 shares of the company’s stock worth $197,000 after acquiring an additional 4,780 shares in the last quarter. Finally, Semanteon Capital Management LP purchased a new stake in Evolus in the third quarter worth $912,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.